RU2015141713A - Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний - Google Patents
Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний Download PDFInfo
- Publication number
- RU2015141713A RU2015141713A RU2015141713A RU2015141713A RU2015141713A RU 2015141713 A RU2015141713 A RU 2015141713A RU 2015141713 A RU2015141713 A RU 2015141713A RU 2015141713 A RU2015141713 A RU 2015141713A RU 2015141713 A RU2015141713 A RU 2015141713A
- Authority
- RU
- Russia
- Prior art keywords
- sulfonyl
- phenyl
- benzamide
- amino
- pyran
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 4
- 239000003814 drug Substances 0.000 title claims 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- -1 4'-chlorobiphenyl-2-yl Chemical group 0.000 claims 22
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 15
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims 2
- JNYQYJFXTVUFGC-UHFFFAOYSA-N 5-[2-[[4-[4-[[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylcarbamoyl]phenyl]piperazin-1-yl]methyl]phenyl]-n-(2-phenyl-1,3-benzoxazol-5-yl)furan-2-carboxamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3OC(=CC=3)C(=O)NC=3C=C4N=C(OC4=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCC1CCOCC1 JNYQYJFXTVUFGC-UHFFFAOYSA-N 0.000 claims 1
- KGQKHDAFBKFNHO-UHFFFAOYSA-N 6-[3-(1-adamantyl)-4-hydroxyphenyl]-n-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonylnaphthalene-2-carboxamide Chemical compound C1=C(C23CC4CC(CC(C4)C2)C3)C(O)=CC=C1C(C=C1C=C2)=CC=C1C=C2C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCCCC1 KGQKHDAFBKFNHO-UHFFFAOYSA-N 0.000 claims 1
- WTIWXNQNRBTBKY-UHFFFAOYSA-N 6-[3-(1-adamantyl)-4-methoxyphenyl]-n-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonylnaphthalene-2-carboxamide Chemical compound C1=C(C23CC4CC(CC(C4)C2)C3)C(OC)=CC=C1C(C=C1C=C2)=CC=C1C=C2C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCCCC1 WTIWXNQNRBTBKY-UHFFFAOYSA-N 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- RSDOASZYYCOXIB-UHFFFAOYSA-N beta-alaninamide Chemical compound NCCC(N)=O RSDOASZYYCOXIB-UHFFFAOYSA-N 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- YCGAILBJRWNKLY-UHFFFAOYSA-N n-[1-[4-[[3-nitro-4-(oxan-4-ylamino)phenyl]sulfonylcarbamoyl]phenyl]piperidin-4-yl]adamantane-1-carboxamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC2)NC(=O)C23CC4CC(CC(C4)C2)C3)=CC=C1NC1CCOCC1 YCGAILBJRWNKLY-UHFFFAOYSA-N 0.000 claims 1
- AJZLLBZLGGUXKR-UHFFFAOYSA-N n-cyclooctyl-5-[2-[[4-[4-[[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylcarbamoyl]phenyl]piperazin-1-yl]methyl]phenyl]furan-2-carboxamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3OC(=CC=3)C(=O)NC3CCCCCCC3)CC2)=CC=C1NCC1CCOCC1 AJZLLBZLGGUXKR-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002471 spleen cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31757510P | 2010-03-25 | 2010-03-25 | |
| US61/317,575 | 2010-03-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012145298/04A Division RU2568611C2 (ru) | 2010-03-25 | 2011-03-10 | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015141713A3 RU2015141713A3 (enExample) | 2018-12-28 |
| RU2015141713A true RU2015141713A (ru) | 2018-12-28 |
Family
ID=43858249
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012145298/04A RU2568611C2 (ru) | 2010-03-25 | 2011-03-10 | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
| RU2015141713A RU2015141713A (ru) | 2010-03-25 | 2011-03-10 | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012145298/04A RU2568611C2 (ru) | 2010-03-25 | 2011-03-10 | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8188077B2 (enExample) |
| EP (3) | EP2550258B1 (enExample) |
| JP (1) | JP5959501B2 (enExample) |
| KR (1) | KR20130040834A (enExample) |
| CN (2) | CN105218483A (enExample) |
| AU (1) | AU2011229862B2 (enExample) |
| BR (1) | BR112012024382A2 (enExample) |
| CA (1) | CA2792276A1 (enExample) |
| DK (1) | DK2550258T3 (enExample) |
| ES (1) | ES2553143T3 (enExample) |
| HK (2) | HK1200444A1 (enExample) |
| HR (1) | HRP20151218T1 (enExample) |
| HU (1) | HUE026241T2 (enExample) |
| IL (2) | IL221771A (enExample) |
| MX (1) | MX2012011086A (enExample) |
| NZ (2) | NZ628298A (enExample) |
| PL (1) | PL2550258T3 (enExample) |
| PT (1) | PT2550258E (enExample) |
| RS (1) | RS54388B1 (enExample) |
| RU (2) | RU2568611C2 (enExample) |
| SG (2) | SG184094A1 (enExample) |
| SI (1) | SI2550258T1 (enExample) |
| SM (1) | SMT201600016B (enExample) |
| TW (2) | TWI535713B (enExample) |
| WO (1) | WO2011119345A2 (enExample) |
| ZA (1) | ZA201206837B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| ES2536090T3 (es) | 2009-01-19 | 2015-05-20 | Abbvie Inc. | Agentes inductores de la apoptosis para el tratamiento del cáncer y enfermedades inmunitarias y autoinmunitarias |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US8952169B2 (en) | 2012-05-22 | 2015-02-10 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
| IN2015MN00002A (enExample) | 2012-07-09 | 2015-10-16 | Lupin Ltd | |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| KR101643280B1 (ko) * | 2014-09-02 | 2016-07-28 | 한국원자력의학원 | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피페리딘카복사마이드 유도체 및 이의 의학적 용도 |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| PL3381896T3 (pl) * | 2015-11-27 | 2023-05-08 | Taiho Pharmaceutical Co., Ltd. | Związek bifenylowy lub jego sól |
| KR102359439B1 (ko) * | 2017-03-31 | 2022-02-09 | (주)아모레퍼시픽 | 벤조산아마이드 화합물 및 사이클로덱스트린 용해보조제를 포함하는 조성물 |
| WO2018216795A1 (ja) * | 2017-05-26 | 2018-11-29 | 大鵬薬品工業株式会社 | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| FI3788042T3 (fi) | 2018-04-29 | 2025-04-07 | Beigene Switzerland Gmbh | Bcl-2-inhibiittoreita |
| RU2693378C1 (ru) * | 2018-10-02 | 2019-07-02 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Фармацевтическая композиция, проявляющая цитотоксическое действие в отношении клеток рака мочевого пузыря человека |
| AU2020292965A1 (en) * | 2019-06-10 | 2022-01-27 | Adc Therapeutics Sa | Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| TW202200574A (zh) | 2020-04-15 | 2022-01-01 | 英屬開曼群島商百濟神州有限公司 | Bcl-2抑制劑 |
| US20240166644A1 (en) * | 2021-02-01 | 2024-05-23 | Ascentage Pharma (Suzhou) Co., Ltd. | Sulfonyl benzamide derivatives as bcl-2 inhibitors |
| CA3211639A1 (en) | 2021-03-19 | 2022-09-22 | Volodymyr KYSIL | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors |
| WO2024032776A1 (en) * | 2022-08-12 | 2024-02-15 | Fochon Biosciences, Ltd. | Compounds as bcl-2 inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5892655A (ja) * | 1981-11-27 | 1983-06-02 | Otsuka Chem Co Ltd | カ−バメイト系誘導体、その製造方法及びその誘導体を有効成分として含有する殺虫剤 |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| UY26942A1 (es) * | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US20050049594A1 (en) | 2001-04-20 | 2005-03-03 | Wack Michael A. | Dual locking plate and associated method |
| WO2002098848A1 (en) * | 2001-06-06 | 2002-12-12 | Eli Lilly And Company | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents |
| AU4235802A (en) * | 2002-05-20 | 2003-11-27 | Andreas Krumbacher | Combinations flexible apparatus (multiple flexibletrack) |
| ATE375978T1 (de) * | 2002-11-22 | 2007-11-15 | Lilly Co Eli | Benzoylsulfonamide als antitumor-mittel |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
| WO2005117543A2 (en) * | 2004-05-26 | 2005-12-15 | Abbott Laboratories | N-sulfonylcarboximidamide apoptosis promoters |
| DE602004020812D1 (de) | 2004-07-20 | 2009-06-04 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| US20060088886A1 (en) * | 2004-10-25 | 2006-04-27 | Anlong Ouyang | Topiramate analogs |
| KR101533268B1 (ko) * | 2005-05-12 | 2015-07-03 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| EP2121641B1 (en) | 2007-02-15 | 2014-09-24 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands |
| US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| WO2009036035A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| US20090131363A1 (en) | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
| MX2010005395A (es) | 2007-11-16 | 2010-06-02 | Abbott Lab | Metodo para tratar artritis. |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| CN104945311A (zh) | 2009-01-19 | 2015-09-30 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| ES2536090T3 (es) | 2009-01-19 | 2015-05-20 | Abbvie Inc. | Agentes inductores de la apoptosis para el tratamiento del cáncer y enfermedades inmunitarias y autoinmunitarias |
-
2011
- 2011-03-10 AU AU2011229862A patent/AU2011229862B2/en not_active Ceased
- 2011-03-10 NZ NZ628298A patent/NZ628298A/en not_active IP Right Cessation
- 2011-03-10 PT PT117095794T patent/PT2550258E/pt unknown
- 2011-03-10 KR KR1020127027672A patent/KR20130040834A/ko not_active Ceased
- 2011-03-10 RU RU2012145298/04A patent/RU2568611C2/ru not_active IP Right Cessation
- 2011-03-10 MX MX2012011086A patent/MX2012011086A/es active IP Right Grant
- 2011-03-10 SI SI201130660T patent/SI2550258T1/sl unknown
- 2011-03-10 EP EP11709579.4A patent/EP2550258B1/en active Active
- 2011-03-10 HR HRP20151218TT patent/HRP20151218T1/hr unknown
- 2011-03-10 JP JP2013501293A patent/JP5959501B2/ja not_active Expired - Fee Related
- 2011-03-10 SG SG2012068615A patent/SG184094A1/en unknown
- 2011-03-10 WO PCT/US2011/027895 patent/WO2011119345A2/en not_active Ceased
- 2011-03-10 CN CN201510587254.2A patent/CN105218483A/zh active Pending
- 2011-03-10 DK DK11709579.4T patent/DK2550258T3/en active
- 2011-03-10 NZ NZ602055A patent/NZ602055A/en not_active IP Right Cessation
- 2011-03-10 PL PL11709579T patent/PL2550258T3/pl unknown
- 2011-03-10 HU HUE11709579A patent/HUE026241T2/en unknown
- 2011-03-10 RS RS20150756A patent/RS54388B1/sr unknown
- 2011-03-10 CA CA2792276A patent/CA2792276A1/en not_active Abandoned
- 2011-03-10 EP EP15178279.4A patent/EP2957558A3/en not_active Withdrawn
- 2011-03-10 BR BR112012024382A patent/BR112012024382A2/pt not_active IP Right Cessation
- 2011-03-10 EP EP14160660.8A patent/EP2757105A1/en not_active Withdrawn
- 2011-03-10 SG SG10201406608YA patent/SG10201406608YA/en unknown
- 2011-03-10 ES ES11709579.4T patent/ES2553143T3/es active Active
- 2011-03-10 RU RU2015141713A patent/RU2015141713A/ru unknown
- 2011-03-10 CN CN201180015915.4A patent/CN102947283B/zh not_active Expired - Fee Related
- 2011-03-16 US US13/049,569 patent/US8188077B2/en not_active Expired - Fee Related
- 2011-03-25 TW TW100110483A patent/TWI535713B/zh not_active IP Right Cessation
- 2011-03-25 TW TW105106938A patent/TW201623291A/zh unknown
-
2012
- 2012-04-27 US US13/458,968 patent/US8343967B2/en not_active Expired - Fee Related
- 2012-09-04 IL IL221771A patent/IL221771A/en not_active IP Right Cessation
- 2012-09-12 ZA ZA2012/06837A patent/ZA201206837B/en unknown
-
2013
- 2013-06-06 HK HK15100726.4A patent/HK1200444A1/en unknown
-
2014
- 2014-03-25 IL IL231702A patent/IL231702A0/en unknown
-
2016
- 2016-01-15 SM SM201600016T patent/SMT201600016B/it unknown
- 2016-06-17 HK HK16107017.6A patent/HK1219092A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015141713A (ru) | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний | |
| JP2013523636A5 (enExample) | ||
| JP2013512899A5 (enExample) | ||
| US10457638B2 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| RU2012127760A (ru) | Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний | |
| RU2411238C2 (ru) | Цис-2,4,5-триарилимидазолины и их применение в качестве противораковых лекарственных средств | |
| RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| JP2013527202A5 (enExample) | ||
| JPWO2022173032A5 (enExample) | ||
| EP3931183B1 (en) | Compounds with ferroptosis inducing activity and methods of their use | |
| RU2347777C2 (ru) | Двойные агонисты nk1/nk3 для лечения шизофрении | |
| RU2012156844A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2013525318A5 (enExample) | ||
| JP2016517406A5 (enExample) | ||
| JP2013512900A5 (enExample) | ||
| RU2014119976A (ru) | (гетеро)арилциклопропиламины в качестве ингибиторов lsd1 | |
| JP2010504342A5 (enExample) | ||
| NZ703941A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| JP2011524906A5 (enExample) | ||
| RU2012138257A (ru) | Замещенные пирролидин-2-карбоксамиды | |
| US20100210633A1 (en) | Carboxamide compounds and their use | |
| US20220380347A1 (en) | Inhibitors of cysteine proteases and methods of use thereof | |
| US11040964B2 (en) | Compounds and methods of use | |
| WO2021222114A1 (en) | Bcl-2 protein inhibitors | |
| JP2009537542A5 (enExample) |